Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane

Objectives: This article reviews pharmacology, pharmacokinetic properties, clinical efficacy, and safety in metastatic breast cancer patients, as well as the predictive biomarkers for outcome of treatment with pemetrexed-based regimens. Methods: PubMed, Embase, OVID, and the Cochrane Library databas...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li-Yan Zhou, Ye-Hui Shi, Yong-Sheng Jia, Zhong-Sheng Tong
Formato:	article
Lenguaje:	EN
Publicado:	KeAi Communications Co., Ltd. 2015
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/0e85f4e739c54bea9d4344b05a6e51e9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0e85f4e739c54bea9d4344b05a6e51e9
record_format	dspace
spelling	oai:doaj.org-article:0e85f4e739c54bea9d4344b05a6e51e92021-12-02T14:20:50ZPotential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane2095-882X10.1016/j.cdtm.2015.02.008https://doaj.org/article/0e85f4e739c54bea9d4344b05a6e51e92015-03-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X15000092https://doaj.org/toc/2095-882XObjectives: This article reviews pharmacology, pharmacokinetic properties, clinical efficacy, and safety in metastatic breast cancer patients, as well as the predictive biomarkers for outcome of treatment with pemetrexed-based regimens. Methods: PubMed, Embase, OVID, and the Cochrane Library databases were searched from the beginning of each database without any limitations to the date of publication. Search terms were ââpemetrexedââ or ââLY231514ââ or âAlimtaâ, âmetastatic breast cancerâ, and âadvanced breast cancerâ. Results: There were 15 studies (nÂ =Â 1002) meeting our criteria for evaluation. Eight single-agent trials (nÂ =Â 551) and seven using combinations with other agents (nÂ =Â 451) were identified that evaluated pemetrexed for use in patients with metastatic breast cancer. Response rates to pemetrexed as a single agent varied from 8% to 31%, and with combination therapy have been reported to be between 15.8% and 55.7%. With routine supplementation of patients with folic acid, dexamethasone, and vitamin B12, the toxicity profile of these patients was mild, including dose-limiting neutropenia and thrombocytopenia, as well as lower grades of reversible hepatotoxicity and gastrointestinal toxicity. Expression of thymidylate synthase (TS) and other biomarkers are associated with the prognosis and sensitivity for pemetrexed in breast cancer. Conclusion: Pemetrexed has shown remarkable activity with acceptable toxicities for treatment of metastatic breast cancer patients. Translational research on pemetrexed in breast cancer identified biomarkers as well as additional genes important to its clinical activity and toxicity. Further research is needed to clarify the role of pemetrexed in breast cancer treatment in order to guide oncologists. Keywords: Metastatic breast cancer, Chemotherapy, Pemetrexed, Anthracycline, TaxaneLi-Yan ZhouYe-Hui ShiYong-Sheng JiaZhong-Sheng TongKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 1, Iss 1, Pp 27-35 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Li-Yan Zhou Ye-Hui Shi Yong-Sheng Jia Zhong-Sheng Tong Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane
description	Objectives: This article reviews pharmacology, pharmacokinetic properties, clinical efficacy, and safety in metastatic breast cancer patients, as well as the predictive biomarkers for outcome of treatment with pemetrexed-based regimens. Methods: PubMed, Embase, OVID, and the Cochrane Library databases were searched from the beginning of each database without any limitations to the date of publication. Search terms were ââpemetrexedââ or ââLY231514ââ or âAlimtaâ, âmetastatic breast cancerâ, and âadvanced breast cancerâ. Results: There were 15 studies (nÂ =Â 1002) meeting our criteria for evaluation. Eight single-agent trials (nÂ =Â 551) and seven using combinations with other agents (nÂ =Â 451) were identified that evaluated pemetrexed for use in patients with metastatic breast cancer. Response rates to pemetrexed as a single agent varied from 8% to 31%, and with combination therapy have been reported to be between 15.8% and 55.7%. With routine supplementation of patients with folic acid, dexamethasone, and vitamin B12, the toxicity profile of these patients was mild, including dose-limiting neutropenia and thrombocytopenia, as well as lower grades of reversible hepatotoxicity and gastrointestinal toxicity. Expression of thymidylate synthase (TS) and other biomarkers are associated with the prognosis and sensitivity for pemetrexed in breast cancer. Conclusion: Pemetrexed has shown remarkable activity with acceptable toxicities for treatment of metastatic breast cancer patients. Translational research on pemetrexed in breast cancer identified biomarkers as well as additional genes important to its clinical activity and toxicity. Further research is needed to clarify the role of pemetrexed in breast cancer treatment in order to guide oncologists. Keywords: Metastatic breast cancer, Chemotherapy, Pemetrexed, Anthracycline, Taxane
format	article
author	Li-Yan Zhou Ye-Hui Shi Yong-Sheng Jia Zhong-Sheng Tong
author_facet	Li-Yan Zhou Ye-Hui Shi Yong-Sheng Jia Zhong-Sheng Tong
author_sort	Li-Yan Zhou
title	Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane
title_short	Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane
title_full	Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane
title_fullStr	Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane
title_full_unstemmed	Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane
title_sort	potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane
publisher	KeAi Communications Co., Ltd.
publishDate	2015
url	https://doaj.org/article/0e85f4e739c54bea9d4344b05a6e51e9
work_keys_str_mv	AT liyanzhou potentialroleofpemetrexedinmetastaticbreastcancerpatientspretreatedwithanthracyclineortaxane AT yehuishi potentialroleofpemetrexedinmetastaticbreastcancerpatientspretreatedwithanthracyclineortaxane AT yongshengjia potentialroleofpemetrexedinmetastaticbreastcancerpatientspretreatedwithanthracyclineortaxane AT zhongshengtong potentialroleofpemetrexedinmetastaticbreastcancerpatientspretreatedwithanthracyclineortaxane
_version_	1718391530274684928

Potential role of pemetrexed in metastatic breast cancer patients pre-treated with anthracycline or taxane

Ejemplares similares